Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 52-58

  Poulsen, Hans Skovgaard ^a   Grunnet, Kirsten ^a   Sorensen, Morten ^a   Olsen, Preben ^a   Hasselbalch, Benedikte ^a   Nelausen, Knud ^a   Kosteljanetz, Michael ^b   Lassen, Ulrik ^a  

^a FINSEN LABORATORY   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Bevacizumab; Clinical trial; Glioma; Irinotecan; Recurrent; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; ETOPOSIDE; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BLEEDING; BRAIN HEMORRHAGE; BRAIN TUMOR; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPENDYMOMA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMANGIOPERICYTOMA; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROLACTINOMA; PROTEINURIA; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 58149090856     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802537924     Document Type: Article

References (40)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
2. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms: An update on the multidisciplinary management of malignant glioma. Oncologist 2006;11:165-80.
3. van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer 2006;42:582-8.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
5. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol 1999;17:2572-8.
6. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:29-38.
7. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003;62:297-303.
8. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
9. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39.
10. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
11. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-22.
12. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
14. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
15. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77.
16. Vredenburgh JJ Desjardins A Herndon JE 2nd, Dowell JM Reardon DA Quinn JA et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9.
17. Vredenburgh JJ Desjardins A Herndon JE 2nd, Marcello J Reardon DA Quinn JA et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9.
18. Norden AD, Young GS, Satayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-87.
19. Prados MD, Lamborn K, Yung WKA, Jaeckle K, Robins HI, Mehta M, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro Oncol 2006;8:189-93.
20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007;114:97-109.
21. NCI Common Terminology Criteria for Adverse Events v.3.0 (CTCAE) [published 2006 Aug 8; cited 2008 Sep 15]. Available from: http:/ctep.cancer. gov/forms/CTCAEv3.pdf.
22. MacDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
23. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005;7: 369:(abstr 342).
24. Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 2008;164:588-94.
25. Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998;22:816-26.
26. Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, et al. Vascular endothelial growth factor (VEGF) in astrocytic gliomas: a prognostic factor? J Neurooncol 1999;45:117-25.
27. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004;108:43-8.
28. Perdiki M, Korkolopoulou P, Thymara I, Agrogiannis G, Piperi C, Boviatsis E, Kotsiakis X, et al. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem 2007;295:75-83.
29. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008;29:419-24.
30. Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to Bevacizumab and Irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007;25:4714-21.
31. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade glioma. J Clin Oncol 2000;18:708-15.
32. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 2001;51:41-5.
33. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 2007;110:13-24.
34. Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004;67:191-200.
35. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolamide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81:271-7.
36. Kesari S, Schiff D, Gigas DC, Gigas DC, Batchelor TT, Muzikansky A, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007;9:354-63.
37. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003;15:2299-304.
38. Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007;23:181-98.
39. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33(5 Suppl 10):S26-34.
40. Kondziolka D, Bernstein M, Resch L, Tator CH, Fleming JF, Vanderlinden RG, et al. Significance of hemorrhage into brain tumors: clinicopathological study. J Neurosurg 1987;67:852-7.